A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003)
Purpose
The goal of the study is to see what happens to levels of MK-1708 a person's body over time. Researchers will compare what happens to MK-1708 in the body when it is given with or without a medicine called itraconazole.
Condition
- Alzheimer's Disease
Eligibility
- Eligible Ages
- Between 18 Years and 50 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
The key inclusion criteria include but are not limited to the following: - Is in good health before randomization - Has a body mass index (BMI) ≥18.5 and ≤32 kg/m^2, inclusive
Exclusion Criteria
The key exclusion criteria include but are not limited to the following: - Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases - Has a history of cancer
Study Design
- Phase
- Phase 1
- Study Type
- Interventional
- Allocation
- Non-Randomized
- Intervention Model
- Sequential Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Period 1: MK-1708 |
Participants will receive a single oral dose of MK-1708 on Day 1. |
|
|
Experimental Period 2: MK-1708 and Itraconazole |
A washout period of at least 10 days will occur between MK-1708 dosing in Period 1 and the first itraconazole dosing in Period 2. In Period 2, participants will receive itraconazole twice daily on Day 1 and once daily on Days 2 through Day 19. Participants will also receive a single oral dose of MK-1708 on Day 4. |
|
Recruiting Locations
More Details
- NCT ID
- NCT06586606
- Status
- Completed
- Sponsor
- Merck Sharp & Dohme LLC